Home/Southern African Journal of HIV Medicine/Article Record
Peer-Reviewed Article November 7, 2019

Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update

Are you an author of this work?Link to your sovereign AfriScholar profile
Published in: Southern African Journal of HIV Medicine
Publisher: AOSIS • South Africa • 1608-9693 • 2078-6751
DOI: https://doi.org/10.4102/sajhivmed.v20i1.1030

Abstract

role of corticosteroids in CM. 8,9 Finally, international and local advocacy efforts have resulted in increasing, yet still limited, access to flucytosine and a reduced cost of liposomal amphotericin B for the treatment of CM. 10 Summary of major changes to the guideline1. We now recommend CrAg screening for all adults or adolescents with a CD4 + T-lymphocyte (CD4) count < 200 cells/µL who are initiating ART for the first time, switching after ART failure or re-entering into care after prior disengagement.2. Reflex laboratory CrAg screening is recommended as the preferred approach in South Africa, although alternative approaches may be more suitable for other countries in Southern Africa. 3. To diagnose CM, lumbar puncture (LP) is recommended for all patients with a new positive CrAg screening test result.4. The recommended induction regimen for CM is 1 week of amphotericin B deoxycholate (1 mg/kg/day) and flucytosine (100 mg/kg/day in four divided doses), followed by 1 week of fluconazole (1200 mg daily for adults; 12 mg/kg/day for children and adolescents up to a maximum of 800 mg daily).5. We have recommended alternative induction regimensfor CM among patients with renal dysfunction, including liposomal amphotericin B-based options.6.A higher dose of fluconazole is now recommended during the 8-week consolidation phase for CM (800 mg daily for adults; 12 mg/kg/day for children and adolescents up to a maximum of 800 mg daily).7. Maintenance treatment for CM is recommended to be continued for at least 12 months and until a single CD4 count is > 200 cells/µL and the HIV viral load is suppressed.8.We have included new recommendations for the prevention, monitoring and management of flucytosine toxicities.9.Although a manometer is the most accurate way to measure raised intracranial pressure, we have suggested alternative options for assessment of elevated pressure when it is unavailable.10.Patients with a positive blood CrAg test result in whom CM is ruled out by LP (a negative cerebrospinal fluid [CSF] CrAg test is the most rapid method to establish this) should be given oral fluconazole alone as induction therapy (adults: 1200 mg for 2 weeks).Antiretroviral treatment may be commenced immediately.11.We recommend immediate referral for LP in all patients with a new positive blood CrAg test who initiated ART within the 4-week period prior to the CrAg test.Among those with a negative CSF CrAg test (i.e. in whom CM is excluded), ART is recommended to be continued and fluconazole pre-emptive therapy should be initiated.Among those with a new diagnosis of CM during the first 4 weeks of ART, the guideline panel thought that there was clinical equipoise in terms of a decision to continue or interrupt ART.12. Antifungal susceptibility testing is now recommended if a patient has a single relapse episode of CM and other causes have been excluded.

Download Full Text PDFView at PublisherCrossref RecordCrossref XML

Verified Citation Velocity

Recorded scholarly citations in African and international peer-reviewed literature

78
Total Citations

Citations are continuously tracked and harvested across continental OJS endpoints and OpenAlex feeds.